Markus
@MarkusMeyerMD
Followers
33
Following
4
Media
2
Statuses
31
Joined December 2021
Can faster heart rates ELEVATE lives? In 30 years from bench to patient. https://t.co/5KpNzViYSu
news.medtronic.com
Study to evaluate whether a new approach to pacing the heart can improve the lives of patients with heart failure with preserved ejection fraction (HFpEF) who have limited treatment options today...
0
0
0
The president does not have chronic venous insufficiency - he has elevated cardiac filling pressures from bradycardia-mediated HFpEF that put him at risk for AF.
0
0
0
Atria have a functional conduction system that is accessible for CSP https://t.co/9dQgyJ9usv
0
0
1
Another way to give HFpEF patients more room to breathe https://t.co/T5ggfTQGSQ
onlinelibrary.wiley.com
• Cilostazol is an oral PDE-3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short-term heart failure-re...
0
1
1
2024 HCM Guidelines are failing HCM patients with preserved EF again! BETABLOCKERS do NOT improve diastolic function. They are HFpEF in a pill. Not indicated in nHCN https://t.co/DEiVHyeRaG.…
0
0
1
myPACE forever ?? 3-year exposure to personalized accelerated physiological pacing. AHA Poster (#2240 and 2260) Monday 1:30-2:45p.
0
0
2
More background on personalized accelerated physiological pacing as a treatment approach for diastolic dysfunction. https://t.co/WzpAfUIPmg
academic.oup.com
Abstract. Heart failure with preserved ejection fraction (HFpEF) is increasingly prevalent with a high socioeconomic burden. Pharmacological heart rate low
0
0
0
No evidence for inflammation in human myocardial LV transcriptome in advanced HFpEF https://t.co/odlbbADGTv
ahajournals.org
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is increasingly prevalent and has few treatments. The molecular mechanisms and resultant signaling pathways that underlie the...
0
4
5
Without an evidence basis beta-blockers, remain the #1 drug prescribed in HFpEF (flawed rationale and outdated treatment recommendations) https://t.co/eQmP97bpu0
0
0
0
Not all patients with “heart failure” need or benefit from beta blockers. Our analysis showing the potential for an increased risk for HF hospitalization with BB in patients with higher EFs (particularly over 60%).
4
32
81
Fascinating insights into the “why beta-blocker in HFpEF” mystery, thanks @ParagGoyalMD et al. @RyanTedfordMD @KSharmaMD Physician Perspectives on the Use of Beta Blockers in Heart Failure With Preserved Ejection Fraction -
5
14
76